Home Interviews Curasight on the agreement with Curium

Curasight on the agreement with Curium

Curasight comments the Curium deal

Curasight on the agreement with Curium

10 May, 2023

Copenhagen-based Curasight has worked tirelessly to secure a partnership deal for uTRACE. Now, the company finally announces that it has reached a deal with global radiopharmaceuticals specialist Curium, regarding the diagnosis of prostate cancer patients. The agreement include milestone payments of up to 70 MUSD, plus double-digit royalties on future sales. BioStock invited CEO Ulrich Krasilnikoff and Chief Scientific Officer Andreas Kjaer to the studio to learn more about what this means for the company.

Watch the interview with Curasight’s CEO Ulrich Krasilnikoff and Head of Research Andreas Kjaer below.

YouTube video

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev